Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto PA, Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Aglietta M, et al. Among authors: gueli r. Tumori. 2023 Dec;109(6):537-545. doi: 10.1177/03008916231179251. Epub 2023 Jul 7. Tumori. 2023. PMID: 37417313 Free PMC article.
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto P, Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Aglietta M, et al. Among authors: gueli r. Target Oncol. 2021 Nov;16(6):789-799. doi: 10.1007/s11523-021-00850-1. Epub 2021 Nov 10. Target Oncol. 2021. PMID: 34755244 Free PMC article.
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, Ascierto PA, Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B. Atkinson VG, et al. Among authors: gueli r. Cancers (Basel). 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466. Cancers (Basel). 2021. PMID: 34070224 Free PMC article.
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Nigro O, Marrazzo C, Gallerani E, Bascialla L, Gueli R, Grigioni E, De Giorgi A, Giaquinto A, Vallini I, Pinotti G. Nigro O, et al. Among authors: gueli r. Anticancer Drugs. 2020 Jun;31(5):528-532. doi: 10.1097/CAD.0000000000000904. Anticancer Drugs. 2020. PMID: 32011361 Clinical Trial.
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Torrisi R, Palumbo R, De Sanctis R, Vici P, Bianchi GV, Cortesi L, Leonardi V, Gueli R, Fabi A, Valerio MR, Gambaro AR, Tagliaferri B, Pizzuti L, Cazzaniga ME, Santoro A. Torrisi R, et al. Among authors: gueli r. Breast Cancer Res Treat. 2021 Nov;190(1):103-109. doi: 10.1007/s10549-021-06371-9. Epub 2021 Aug 27. Breast Cancer Res Treat. 2021. PMID: 34453206
Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.
Giotta F, Acito L, Candeloro G, Del Medico P, Gadaleta-Caldarola G, Giordano G, Gueli R, Lugini A, Magri V, Mandarà M, Masci G, Pisconti S, Pistelli M, Rizzi A, Salesi N, Schirone A, Scognamiglio G, Tedeschi M, Zucchinelli P. Giotta F, et al. Among authors: gueli r. Oncologist. 2016 Nov;21(11):1298-1305. doi: 10.1634/theoncologist.2016-0022. Epub 2016 Oct 14. Oncologist. 2016. PMID: 27742906 Free PMC article.
14 results